Us External Counterpulsation Devices Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

External counterpulsation devices deliver enhanced external counterpulsation therapy, a non-invasive cardiovascular treatment in which pneumatic cuffs wrapped around a patient's lower limbs inflate and deflate in rhythm with the cardiac cycle to augment diastolic blood flow and coronary perfusion. The U.S. market reached approximately $163 million in 2023 and is projected to approach $272 million by 2030, supported by a well-established reimbursement pathway. Stable Medicare coverage and a growing installed base of treatment-capable facilities underpin steady demand across cardiology practices and hospital outpatient settings.

• •The market is valued at roughly $203 million in 2026 and is expected to reach approximately $272 million by 2030 at a 7.6% CAGR
• •Medicare reimbursement under CPT code 92960 provides structural financial support for ECP therapy delivery nationwide
• •The patient pool is sustained by a rising prevalence of chronic stable angina and congestive heart failure among an aging U.S. population

The growing burden of cardiovascular disease across the U.S. adult population expands the addressable patient base for ECP therapy, particularly among individuals who are poor candidates for surgical revascularization or have exhausted other interventional options. Favorable reimbursement policies reduce financial barriers for both providers and patients, while accumulating clinical evidence supporting ECP efficacy continues to drive broader adoption across cardiac rehabilitation programs and hospital outpatient departments.

• •Rising incidence of chronic angina and heart failure among older U.S. adults directly expands demand for non-invasive treatment alternatives
• •Established Medicare reimbursement reduces cost barriers and incentivizes cardiology departments to offer ECP therapy
• •Clinical evidence demonstrating improved exercise tolerance and quality of life outcomes supports wider provider adoption

The U.S. market can be broadly segmented by device configuration, single-piece integrated systems versus modular multi-component setups, and by end-use setting, including hospital-based cardiac rehabilitation programs, specialty cardiology clinics, and ambulatory surgical centers. The American market overwhelmingly dominates North American market value due to larger healthcare spending, an established reimbursement infrastructure, and a greater installed base of treatment-capable facilities relative to Canada and Mexico.

• •Device types range from fully integrated one-piece units to modular systems allowing incremental component upgrades
• •Hospital outpatient and cardiac rehabilitation departments constitute the dominant end-user segment for ECP treatments
• •The U.S. accounts for the large majority of North American market value, with Canada representing a secondary market characterized by smaller facility adoption rates

Who are the notable companies in the industry?

The market exhibits moderate concentration, with a small number of established manufacturers alongside smaller specialty producers that focus on particular clinical applications or service niches. Most producers follow either a fully integrated device model, designing and manufacturing complete systems in-house, or a component-specialist approach, sourcing subassemblies from medical equipment suppliers. Production and assembly capacity is predominantly U.S.-based to satisfy FDA regulatory requirements and maintain proximity to domestic distribution channels.

• •The competitive structure is moderately concentrated, with a handful of established system manufacturers alongside niche specialty producers
• •Technology routes center on pneumatic compression cuff systems synchronized to the cardiac cycle via ECG or pulse-wave gating
• •Manufacturing and final assembly is largely domestic to meet FDA device regulations and support just-in-time distribution to U.S. treatment facilities

What are the recent trends and outlook?

The market is expected to sustain its 7.6% CAGR through the forecast period, supported by continued clinical validation and expanding provider awareness of ECP reimbursement pathways. Integration of digital monitoring and data analytics into ECP platforms is anticipated to enhance treatment personalization and clinical workflow efficiency. Emerging demand for outpatient and ambulatory cardiovascular care may drive interest in more compact and flexible device configurations suited to non-hospital settings.

• •Digital integration and connected monitoring features are expected to improve treatment tracking and clinical outcome documentation
• •Potential broadening of ECP indications beyond traditional angina applications could expand the addressable patient population
• •Growth in outpatient and ambulatory cardiovascular care models may create demand for more compact, portable device configurations